Oral Administration of a Salmonella enterica -Based Vaccine Expressing Bacillus anthracis Protective Antigen Confers Protection against Aerosolized B. anthracis
Open Access
- 1 April 2007
- journal article
- research article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 75 (4), 1827-1834
- https://doi.org/10.1128/iai.01242-06
Abstract
Bacillus anthracis is the causative agent of anthrax, a disease that affects wildlife, livestock, and humans. Protection against anthrax is primarily afforded by immunity to the B. anthracis protective antigen (PA), particularly PA domains 4 and 1. To further the development of an orally delivered human vaccine for mass vaccination against anthrax, we produced Salmonella enterica serovar Typhimurium expressing full-length PA, PA domains 1 and 4, or PA domain 4 using codon-optimized PA DNA fused to the S. enterica serovar Typhi ClyA and under the control of the ompC promoter. Oral immunization of A/J mice with Salmonella expressing full-length PA protected five of six mice against a challenge with 10 5 CFU of aerosolized B. anthracis STI spores, whereas Salmonella expressing PA domains 1 and 4 provided only 25% protection (two of eight mice), and Salmonella expressing PA domain 4 or a Salmonella -only control afforded no measurable protection. However, a purified recombinant fusion protein of domains 1 and 4 provided 100% protection, and purified recombinant 4 provided protection in three of eight immunized mice. Thus, we demonstrate for the first time the efficacy of an oral S. enterica -based vaccine against aerosolized B. anthracis spores.Keywords
This publication has 24 references indexed in Scilit:
- Immunization against anthrax using Bacillus subtilis spores expressing the anthrax protective antigenVaccine, 2007
- Adaptation of the Endogenous Salmonella enterica Serovar Typhi clyA -Encoded Hemolysin for Antigen Export Enhances the Immunogenicity of Anthrax Protective Antigen Domain 4 Expressed by the Attenuated Live-Vector Vaccine Strain CVD 908- htrAInfection and Immunity, 2004
- Immune Responses toBacillus anthracisProtective Antigen in Patients with Bioterrorism‐Related Cutaneous or Inhalation AnthraxThe Journal of Infectious Diseases, 2004
- Salmonella enterica Serovar Typhimurium Expressing a Chromosomally Integrated Copy of the Bacillus anthracis Protective Antigen Gene Protects Mice against an Anthrax Spore ChallengeInfection and Immunity, 2003
- Salmonellavaccines for use in humans: present and future perspectivesFEMS Microbiology Reviews, 2002
- Optimization of the Cell Wall Microenvironment Allows Increased Production of Recombinant Bacillus anthracis Protective Antigen from B. subtilisApplied and Environmental Microbiology, 2002
- Production and purification of recombinant protective antigen and protective efficacy against Bacillus anthracisLetters in Applied Microbiology, 1998
- The collison nebulizer: Description, performance and applicationJournal of Aerosol Science, 1973
- The Efficiency of Various Liquid Impinger Samplers in Bacterial AerosolsOccupational and Environmental Medicine, 1957
- An apparatus for the study of airborne infectionEpidemiology and Infection, 1952